Examining the variability of neurocognitive functioning in individuals at clinical high risk for psychosis: a meta-analysis
- PMID: 35551176
- PMCID: PMC9098884
- DOI: 10.1038/s41398-022-01961-7
Examining the variability of neurocognitive functioning in individuals at clinical high risk for psychosis: a meta-analysis
Abstract
This study aims to meta-analytically characterize the presence and magnitude of within-group variability across neurocognitive functioning in young people at Clinical High-Risk for psychosis (CHR-P) and comparison groups. Multistep, PRISMA/MOOSE-compliant systematic review (PROSPERO-CRD42020192826) of the Web of Science database, Cochrane Central Register of Reviews and Ovid/PsycINFO and trial registries up to July 1, 2020. The risk of bias was assessed using a modified version of the NOS for cohort and cross-sectional studies. Original studies reporting neurocognitive functioning in individuals at CHR-P compared to healthy controls (HC) or first-episode psychosis (FEP) patients were included. The primary outcome was the random-effect meta-analytic variability ratios (VR). Secondary outcomes included the coefficient of variation ratios (CVR). Seventy-eight studies were included, relating to 5162 CHR-P individuals, 2865 HC and 486 FEP. The CHR-P group demonstrated higher variability compared to HC (in descending order of magnitude) in visual memory (VR: 1.41, 95% CI 1.02-1.94), executive functioning (VR: 1.31, 95% CI 1.18-1.45), verbal learning (VR: 1.29, 95% CI 1.15-1.45), premorbid IQ (VR: 1.27, 95% CI 1.09-1.49), processing speed (VR: 1.26, 95% CI 1.07-1.48), visual learning (VR: 1.20, 95% CI 1.07-1.34), and reasoning and problem solving (VR: 1.17, 95% CI 1.03-1.34). In the CVR analyses the variability in CHR-P population remains in the previous neurocognitive domains and emerged in attention/vigilance, working memory, social cognition, and visuospatial ability. The CHR-P group transitioning to psychosis showed greater VR in executive functioning compared to those not developing psychosis and compared to FEP groups. Clinical high risk for psychosis subjects shows increased variability in neurocognitive performance compared to HC. The main limitation of this study is the validity of the VR and CVR as an index of variability which has received debate. This finding should be explored by further individual-participant data research and support precision medicine approaches.
© 2022. The Author(s).
Conflict of interest statement
AC reports personal fees from Janssen-Cilag and grants from the Carlos III Health Institute outside the submitted work. PFP reports research fees from Lundbeck and honoraria from Lundbeck, Angelini, Menarini, and Boehringer Ingelheim outside the submitted work. No other disclosures were reported.
Figures





Similar articles
-
Neurocognitive Functioning in Individuals at Clinical High Risk for Psychosis: A Systematic Review and Meta-analysis.JAMA Psychiatry. 2021 Jun 16;78(8):859-67. doi: 10.1001/jamapsychiatry.2021.1290. Online ahead of print. JAMA Psychiatry. 2021. PMID: 34132736 Free PMC article.
-
Neuropsychological Test Performance to Enhance Identification of Subjects at Clinical High Risk for Psychosis and to Be Most Promising for Predictive Algorithms for Conversion to Psychosis: A Meta-Analysis.J Clin Psychiatry. 2017 Jan;78(1):e28-e40. doi: 10.4088/JCP.15r10197. J Clin Psychiatry. 2017. PMID: 28129494
-
The magnitude and variability of neurocognitive performance in first-episode psychosis: a systematic review and meta-analysis of longitudinal studies.Transl Psychiatry. 2024 Jan 8;14(1):15. doi: 10.1038/s41398-023-02718-6. Transl Psychiatry. 2024. PMID: 38191534 Free PMC article.
-
Clinical outcomes in individuals at clinical high risk of psychosis who do not transition to psychosis: a meta-analysis.Epidemiol Psychiatr Sci. 2022 Jan 19;31:e9. doi: 10.1017/S2045796021000639. Epidemiol Psychiatr Sci. 2022. PMID: 35042573 Free PMC article.
-
Cognitive Function and Variability in Antipsychotic Drug-Naive Patients With First-Episode Psychosis: A Systematic Review and Meta-Analysis.JAMA Psychiatry. 2024 May 1;81(5):468-476. doi: 10.1001/jamapsychiatry.2024.0016. JAMA Psychiatry. 2024. PMID: 38416480 Free PMC article.
Cited by
-
Jumping to Conclusions: Mechanisms of Cognitive Control in Decision-Making Under Uncertainty.Behav Sci (Basel). 2025 Feb 17;15(2):226. doi: 10.3390/bs15020226. Behav Sci (Basel). 2025. PMID: 40001857 Free PMC article.
-
Long-term outcomes of additional surgery versus surveillance-only clinical decision for early colorectal cancer patients after non-curative endoscopic resection: a meta-analysis.BMC Gastroenterol. 2024 Nov 20;24(1):416. doi: 10.1186/s12876-024-03502-6. BMC Gastroenterol. 2024. PMID: 39567887 Free PMC article.
-
Altered cortical thickness associated with psychotic symptoms and cognitive profiles in involuntarily hospitalized, first-episode, drug-naive patients with schizophrenia.Front Psychiatry. 2025 Jun 24;16:1596991. doi: 10.3389/fpsyt.2025.1596991. eCollection 2025. Front Psychiatry. 2025. PMID: 40630756 Free PMC article.
-
Neurocognitive Deficits in Individuals at Ultra-High-Risk for Psychosis: An Overview of Systematic Reviews.Iran J Psychiatry. 2025 Jan;20(1):111-125. doi: 10.18502/ijps.v20i1.17405. Iran J Psychiatry. 2025. PMID: 40093530 Free PMC article. Review.
-
Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment.Mol Psychiatry. 2023 May;28(5):1902-1918. doi: 10.1038/s41380-023-01949-9. Epub 2023 Jan 23. Mol Psychiatry. 2023. PMID: 36690793 Free PMC article. Review.